The EIF2A Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from HT29 human colorectal adenocarcinoma cells. This product features targeted disruption of the EIF2A gene, encoding a translation initiation factor that operates in cap-independent pathways. The polyclonal format, generated without clonal isolation, captures a broad spectrum of EIF2A mutations, providing a robust model to study loss of function.
HT29 cells, a human colorectal adenocarcinoma line derived from a primary tumor of a 44-year-old female, are a well-established model for intestinal epithelial biology. These cells can undergo differentiation into enterocyte-like cells under appropriate conditions, exhibiting polarity and brush border formation. They harbor mutations in key tumor suppressors and oncogenes, reflecting the genetic landscape of colorectal cancer, and are commonly employed to study signaling pathways and drug responses in this malignancy.
EIF2A mediates cap-independent translation by recognizing internal ribosome entry sites (IRES) in mRNAs, a process activated under cellular stress. Upstream, stress signals such as ER stress and nutrient deprivation stimulate eIF2?? kinases (EIF2AK1-4), which inhibit canonical cap-dependent translation, shifting the balance toward EIF2A-dependent initiation. EIF2A forms complexes with the eIF3 complex, the 40S ribosomal subunit, and initiator tRNAiMet to facilitate ribosome recruitment to IRES-containing transcripts. Key downstream targets include oncogenic and stress-responsive proteins like c-MYC, BCL-2, XIAP, and VEGF.
Disrupting EIF2A in HT29 cells creates a platform to probe IRES-dependent translation in colorectal cancer. Loss of EIF2A is predicted to reduce stress-induced synthesis of c-MYC, BCL-2, XIAP, and VEGF, potentially impairing proliferation, survival, and angiogenesis. The polyclonal configuration averages out clonal effects, ensuring that observed phenotypes are representative of EIF2A loss rather than artifacts of single-cell cloning. Moreover, HT29??s capacity for differentiation allows examination of EIF2A??s role in both undifferentiated and differentiated colorectal cancer states.
Researchers can use these polyclonal knockout cells in a variety of assays to investigate EIF2A function. Western blotting and RT-qPCR quantify EIF2A and target expression; luciferase reporters with IRES elements measure cap-independent translation activity; polysome profiling assesses translational efficiency; and cellular assays of proliferation, apoptosis under ER stress, and colony formation provide functional readouts. These applications support the identification of EIF2A-dependent mRNAs and the evaluation of EIF2A as a therapeutic target in colorectal cancer. For additional information, please contact Ascent Research.
